BC
NVS icon

Bridgefront Capital’s Novartis NVS Stock Holding History

Bridgefront Capital’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$480K Sell
3,062
-4,342
-59% -$651K 0.13% 268
2026
Q1 		$1.13M Buy
+7,404
New +$1.13M 0.28% 104
2025
Q3 		– Sell
-6,488
Closed -$785K – 750
2025
Q2 		$785K Sell
6,488
-2,665
-29% -$300K 0.21% 153
2025
Q1 		$1.02M Buy
9,153
+498
+6% +$53K 0.29% 81
2024
Q4 		$842K Buy
+8,655
New +$923K 0.28% 93

Other funds holding NVS

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bridgefront Capital's NVS Position: Q2 2026 in Review

Bridgefront Capital reduced its Novartis (NVS) stake by 59% in Q2 2026, selling an estimated $651K and leaving 3,062 shares worth $480K. The position accounts for 0.13% of the portfolio, ranked #268.

Bridgefront Capital first reported a position in NVS in Q4 2024 and has held it in 5 quarters since. The position peaked at $1.13M in Q1 2026. 1,614 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Bridgefront Capital held 3,062 shares of Novartis worth $480K as of Q2 2026.
  • Bridgefront Capital sold 4,342 Novartis shares in Q2 2026, an estimated $651K.
  • Novartis made up 0.13% of Bridgefront Capital's portfolio in Q2 2026, its #268 holding.
  • Bridgefront Capital first reported a position in Novartis in Q4 2024 and has held it in 5 quarters since.
  • Bridgefront Capital's Novartis position peaked at $1.13M in Q1 2026.
  • 1,614 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.